KOL Community
Peer Reviews
Freya Biosciences collaborates closely with influential key opinion leaders in the scientific community, leveraging their expertise and insights to propel forward our clinical advancements in the field of women’s reproductive health.
There is awareness of the negative association between dysbiosis in the reproductive tract and IVF outcome, but there are limited therapeutic options for clinicians to offer. It’s very frustrating for both doctors and women undergoing IVF. I am very excited by Freya’s innovative approach and progress in developing much needed therapeutics in this area
The scientific evidence demonstrating the link between the vaginal microbiota, inflammation, and reproductive tract health continues to grow every year. However, we have never had an intervention that could change the vaginal microbiota in a meaningful way. "Resetting" the microbiota with Freya’s FB101 will not only be a powerful research tool, but the potential positive impact on women and their babies is enormous.
As a proud co-founder, I am thrilled to see the progress of Freya in developing therapeutics to address the high unmet medical needs for women. There has for too long been a gap in the development of therapeutics in Women’s Health. Freya’s work is grounded in cutting edge science and has the potential to positively impact the lives of women all around the world.
Previous
Next
There is awareness of the negative association between dysbiosis in the reproductive tract and IVF outcome, but there are limited therapeutic options for clinicians to offer. It’s very frustrating for both doctors and women undergoing IVF. I am very excited by Freya’s innovative approach and progress in developing much needed therapeutics in this area period.
The scientific evidence demonstrating the link between the vaginal microbiota, inflammation, and reproductive tract health continues to grow every year. However, we have never had an intervention that could change the vaginal microbiota in a meaningful way. "Resetting" the microbiota with Freya’s therapeutics will not only be a powerful research tool, but the potential positive impact on women and their babies is enormous.
As a proud co-founder, I am thrilled to see the progress of Freya in developing therapeutics to address the high unmet medical needs for women. There has for too long been a gap in the development of therapeutics in Women’s Health. Freya’s work is grounded in cutting edge science and has the potential to positively impact the lives of women all around the world.
